Countries covered: Denmark
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts.
Please note: This is delivered as a Zip file.
Additional Information
The size of the pharmaceutical market in Denmark is estimated to be US$3.9 billion in 2009, equal to US$711 per capita. The primary care sector constitutes nearly three quarters of the total market size. The market is expected to expand by 8.0% per annum between 2009 and 2014. By 2014, the market is estimated to be worth US$6.4 billion, equal to US$1,134 per capita.
Denmark has a stable political system and a stable economy. However, Denmark is likely to be affected by the global economic downturn, with GDP real growth expected to fall to -3.5% in 2009, according to figures from the Economist Intelligence Unit, and gradually rising to reach a real growth of 2.0% in 2014.
Due to the presence of Novo Nordisk, Denmark is a major global supplier of insulin in retail form. This has resulted in a long-standing balance of trade surplus, which was in excess of US$4.7 billion in 2008. Between 2004 and 2008, imports increased by a CAGR of 11.9% to US$3.2 billion, while exports increased by a CAGR of 10.5% to US$7.9 billion.
Healthcare expenditure has continued its steady growth in the past few years, increasing by 7.1% to reach DKK118.3 billion (US$21.7 billion) in 2007, with private expenditure accounting for around 16% of the total.
Although companies are free to set their own prices, products will only be reimbursed at the level of the lowest generic drug in each class unless it can be shown that there is a distinct therapeutic benefit. This has proved to be an effective way to drive pharmaceutical prices down.
Related Reports:
Snapshots Hungary Pharmaceuticals 2009
Snapshots Poland Pharmaceuticals 2009
Snapshots South Africa Pharmaceuticals 2009
Snapshots Spain Pharmaceuticals 2009
Snapshots Venezuela Pharmaceuticals 2009
Australia Pharmaceuticals and Healthcare Report Q1 2010
Thailand Pharmaceuticals and Healthcare Report Q1 2010
Poland Pharmaceuticals and Healthcare Report Q1 2010
Argentina Pharmaceuticals and Healthcare Report Q1 2010
Kenya Pharmaceuticals and Healthcare Report Q1 2010
|
(0 items)
